Orphanet: Alpha N acetylgalactosaminidase deficiency type 3
x

Search for a rare disease

* (*) mandatory field

Other search option(s)

Suggest an update

(*) Required fields.

Attention

Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.

Orphanet doesn't provide personalised answers. To get in touch with the Orphanet team, please contact

Information provided in your contribution (including your email address) will be stocked in .CSV files that will be sent as an email to Orphanet's teams. These emails might be conserved in the teams' mailboxes, in our backoffice servers but will not be registered in our databases (for more information see our section General Data Protection Regulation and data privacy (GDPR) and Confidentiality).

Captcha image

Alpha-N-acetylgalactosaminidase deficiency type 3

Disease definition

A rare clinically heterogeneous type of NAGA deficiency with developmental, neurologic and psychiatric manifestations presenting at an intermediate age.

ORPHA:79281

Classification level: Subtype of disorder
  • Synonym(s):
    • NAGA deficiency type 3
    • Schindler disease type 3
  • Prevalence: <1 / 1 000 000
  • Inheritance: Autosomal recessive 
  • Age of onset: Childhood
  • ICD-10: E77.1
  • OMIM: 609241
  • UMLS: C1836545
  • MeSH: -
  • GARD: 3903
  • MedDRA: -

Summary

Epidemiology

Prevalence of this disorder is not known but less than 20 cases have been reported to date for NAGA deficiency

Clinical description

A very wide spectrum of signs, with a juvenile onset, has been described including asymptomatic patients at the time of diagnosis. Manifestations seen in clinically overt cases may include epilepsy of variable severity, psychomotor retardation, intellectual impairment, autism, strabismus and cataract.

Etiology

Compound heterozygous or homozygous mutations of the alpha-N-acetylgalactosaminidase gene (NAGA; 22q13.2) have been reported in affected patients but also occasionally in their healthy siblings. These mutations lead to the dysfunction, instability and rapid degradation of the lysosomal protein NAGA.

Genetic counseling

Transmission is autosomal recessive and genetic counseling is possible.

- Last update: June 2013

  A summary on this disease is available in Deutsch (2013) Español (2013) Italiano (2013) Nederlands (2013) Polski (2013, pdf)

Additional information

Further information on this disease

Patient-centred resources for this disease

Research activities on this disease

Specialised Social Services

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.